Vermillion, Inc. (NASDAQ:VRML)

this company reminds me of a certain politician - - lots of talk, but no positive action or follow through that makes economic sense

This goes out to the twerp who got the weak-kneed pencil pushers at MF to delete my last red thumb pitch on Vermilion, which was one of my best.

Vermilion is bankruptcy chow. They've made an industry out of deluding muppets that somehow they'll be able to convert their spurious ovarian cancer test into positive cash flow. Many press releases, revenues and profits not so much.

You wanted a dry boring pitch with no partial naughty words, you got it.

http://caps.fool.com/Pitch/VRML/4995537/vrml-vermillion-inc-other-otc-.aspx?

Recent spike in price has faded. Development-stage pharma in between major news.

I'm betting that the recent pop was a speculative overreaction. A patent doesn't automatically translate into revenue, and definitely not necessarily into profits.

TMF Stock Spam. Garbage.

Current testing for ovarian cancer, when a mass is detected, is just slightly better than a coin flip. An ovary's fate compares to a tonsil's in the sixties. With the price of gasoline blowing past $4 a gallon and escalating "greens fees" at the country club, most gynecologic oncologists will have to start doing elective plastic surgery on the side, once Vermillion's OVA1 test becomes the new standard.

One of the best buys for 2011, existing OVA1 product has double digit growth quarter on quarter. New PAD test will generate hype sometimes in the middle of the year. You get existing business and hype, best of both worlds.

They have several patents on a global bases. OVAR1 for ovarian cancer, and they just received one for PAD. The stock price has been up to $34 and I am sure it will go well beyond $34 on this run.

Fremont ,CA & Diagnostic Substances could get some attention after end of year tax dip.

Ovarian cancer drug maker.

Coverage initiated by Wedbush - Outperform - Target $10

52 Week Range $0.04 - $34

Short Interest Days to Cover - 7.88

bravobevo

If I said about Bonton that their financials are horrible, then Vermillion is ten times worse.
Cash barely covers accounts payables, in addition debt of 10M and around 250M in negative earnings with market cap of 114M?
Motto - "Your health, our passion." - Sorry VRML, this is about business right now.
If I was a seer - then I don't foresee much success for this company in the future.

VRML, Vermillion, Inc. (Other OTC: VRML.PK)

June 18th, 2010

Last Price: $13.50
52wk Range: 0.01 - 34.00

VRML is a molecular diagnostics company based in Fremont, California.

Announced just recently the European Patent Office has issued a Decision to Grant patent number 1,493,741 entitled "Use of Biomarkers for Detecting Ovarian Cancer" to the Company.

The patent claims are directed to biomarker combinations for the diagnosis and management of ovarian cancer and to the measurement of the biomarkers by a variety of methods, including mass spectrometry and immunoassay.

Check out the Year to Date chart below to see the growth spread since Mid September 2009.

About VRML

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health.

Find out more about VRML at their website: www.vermillion.com